BioDelivery Sciences International, Inc. Announces Participation
at the NanoBioTech Conference in San Francisco
NEWARK, N.J., April 6 /PRNewswire-FirstCall/ -- BioDelivery Sciences
International, Inc. announced today their participation in the NanoBioTech
Conference in San Francisco, CA on April 15th & 16th, 2004. Dr. Raphael Mannino,
Chief Science Officer of BDSI, will be a guest speaker Friday the 16th.
"Nanocochleates are the most advanced oral delivery technology using
nanoparticles yet developed for human and animal usage. Uniquely, they are made
from all-natural food components consisting of inexpensive soy- phospholipid and
calcium. They enable targeted-delivery to specific cell types within the body. Smart Pharmaceuticals(TM) using the nanocochleate delivery technology have the
potential to play a significant role in biodefense programs," said Dr Raphael
Mannino. "Additional commercial opportunities include enhanced antimicrobials to
deal with drug resistant infections, delivery of fragile micronutrients in
processed foods, and applications to siRNA, a promising new class of
oligonucleotides that is extremely susceptible to enzymatic degradation." With the signing of the 21st Century Nanotechnology Research andDevelopment
Act, guaranteeing $3.7 billion in funding for research and training, the
Nanotech industry is poised for explosive growth in the next decade. Biotechnology and medicine are areas where nanotech has already begun to have an
effect; and an even larger impact is expected as the emerging science is
developed into commercial products.
BioDelivery Sciences International, Inc. is a biotechnology company that is
developing and seeking to commercialize a patented delivery technology designed
for a potentially broad base of pharmaceuticals, vaccines, over-the- counter
drugs, and nutraceuticals and, through its subsidiary, Bioral Nutrient Delivery,
LLC, micronutrients in processed foods and beverages and personal care
products.
Note: Except for the historical information contained herein, this press release
contains forward-looking statements that involve risks and uncertainties. Such
statements are subject to certain factors, which may cause the Company's results
to differ. Factors that maycause such differences include, but are not limited
to, the Company's ability to accurately forecast the demand for each of its
licensed technology and products associated therewith, the gross margins
achieved from the sale of those products and the expenses and other cash needs
for the upcoming periods, the Company's ability to obtain raw materials from its
contract manufacturers on a timely basis if at all, the Company's need for
additional funding, uncertainties regarding the Company's intellectual property
and other research, development, marketing and regulatory risks and certain
other factors that may affect future operating results and are detailed in the
company's filings with the Securities and Exchange Commission.
L.G. Zangani, LLC provides financial public relations service to the Company.
As such L.G. Zangani, LLC and/or its officers, agents and employees, receives
remuneration for public relations and or other services in the form of monies,
capital stock in the Company, warrants or options to purchase capital in the
Company. DATASOURCE: BioDelivery Sciences International, Inc.
CONTACT: Francis E. O'Donnell, Jr., M.D, President and CEO of BioDelivery Sciences International, Inc., +1-973-972-0015, or Dawn Moore of L.G. Zangani, LLC, +1-908-788-9660 Web site: http://www.bdsinternational.com/
|